Stock Screener App

Gratuito -

Installare

0.72

1.41% 0.01

Pre-mercato: .72

Citius Pharmaceuticals Inc (CTXR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CTXR Giù? Forum Previsione Frazionamento azionario

Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie

Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - Traders Union

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq

Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn

Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn

If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan

Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn

Citius Oncology inks exclusive European distribution pact with Uniphar - MSN

Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn

Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn

CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN

Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn

Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal

CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus

Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Canada

Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Finviz

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace

Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks

Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com

LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan

Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn

Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance

33 Stocks That Should Double in 3 Years - Insider Monkey

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace

Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks

Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks

Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView

Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times

CTXR Should I Buy - Intellectia AI

Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView

CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine

Citius Pharmaceuticals Secures $3.8 Million Through New Jersey Economic Development Program - citybiz

Citius Pharmaceuticals (CTXR) Secures $3.8M Through NJ Tax Progr - GuruFocus

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire

Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz

Market Pulse: Can Citius Pharmaceuticals Inc lead its sector in growthJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn

Resistance Check: Can GRNQ maintain sales growthWeekly Market Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Patterns Watch: Will USAC outperform small cap indexesWeekly Loss Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Activity Recap: How does USBPRA perform in inflationary periodsBull Run & Weekly Momentum Stock Picks - baoquankhu1.vn

Analyst Downgrade: Is NVGS forming bullish engulfing patternsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn

Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive

Dip Buying: Will Citius Pharmaceuticals Inc benefit from rate cutsJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn

CVI and Heights disclose 9.9% Citius Pharmaceuticals (CTXR) stake - Stock Titan

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com

FOMO Trade: Is now the right time to enter MAPSMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn

Can Citius Pharmaceuticals Inc. stock continue upward trendWall Street Watch & Free High Return Stock Watch Alerts - mfd.ru

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt

Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve

ROIV

$27.36

1.82%

RPRX

$47.03

3.20%

MRNA

$53.54

4.29%

BNTX

$88.77

2.26%

ONC

$283.45

2.81%

INSM

$148.31

6.59%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters